A Brief Study about HDACs: Novel Pharmacological Target in Diabetic Nephropathy | Chapter 4 | New Frontiers in Medicine and Medical Research Vol. 13
The study's main goal was to figure out how HDACs play a role in the pathophysiology of Diabetic Nephropathy and whether targeting certain HDACs could help halt the progression of the disease. Benefits and downsides of HDAC inhibitors, as well as potential challenges In Diabetic Nephropathy, HDAC inhibitors have various advantages: TGF-beta 1 decreased, Collagen I decreased, Fibronectin decreased-SMA decreased-cadherin decreased, TGF-beta 1 decreased, Collagen I decreased, Fibronectin decreased-SMA decreased, TGF-beta 1 decreased, TGF-beta 1 decreased, TGF-beta 1 decreased, TGF-beta 1 decreased, TGF- Reduces the effects of eNOS, iNOS, and TGF-1 on fibrogenesis, apoptosis, and DNA damage. Klotho is preserved. Inhibits the Wnt signalling pathway. EGFR pathway inactivation Insulin sensitivity is improved. Insulin resistance and Beta cell proliferation are reduced. Apoptosis is reduced. Nephrin and podocin are restored. Inflammatory protein is suppressed. Insulin secretion increase...